Efficacy of Daily IV Administration of Dornase Alfa Up to 14 Days Post Subarachnoid Hemorrhage on Functional Independence At 6 Months

Exclusion Criteria

• •Unidentified date of aneurysm rupture / rebleeding
• •Severe infections
• •Patient with impaired renal function (GFR \< 60ml/min/1.73m2 or serum creatinine \>1.5 mg/dL)
• •Immediate complications of neurosurgical intervention or embolization
• •Known hypersensitivity to dornase alfa, Chinese hamster ovary cell products or product excipients.
• •Previous disability (mRS\>1 prior to SAH)
• •Pregnant or breast-feeding women (negative urine pregnancy test for women aged 49 or under)
• •Participation in another interventional drug or medical device clinical trial within the 30 days prior to inclusion.